Literature DB >> 18566364

Dendritic cells as killers: mechanistic aspects and potential roles.

Camille Chauvin1, Régis Josien.   

Abstract

Dendritic cells (DC) are professional APC endowed with the unique capacity to activate naive T cells. DC also have important effector functions during the innate immune response, such as pathogen recognition and cytokine production. In fact, DC represent the crucial link between innate and adaptive immune responses. However, DC are quite heterogeneous and various subsets endowed with specific pathogen recognition mechanisms, locations, phenotypes, and functions have been described both in rodents and in humans. A series of studies indicated that rodent as well as human DC could also mediate another important innate function, i.e., cell-mediated cytotoxicity, mostly toward tumor cells. In this article, we will review the phenotypes of these so-called killer DC, their killing mechanism, and putative implication in the immune response.

Entities:  

Mesh:

Year:  2008        PMID: 18566364     DOI: 10.4049/jimmunol.181.1.11

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Agonist antibody that induces human malignant cells to kill one another.

Authors:  Kyungmoo Yea; Hongkai Zhang; Jia Xie; Teresa M Jones; Chih-Wei Lin; Walter Francesconi; Fulvia Berton; Mohammad Fallahi; Karsten Sauer; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-20       Impact factor: 11.205

2.  Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells.

Authors:  Ying Qiu; Ming-Bao Xu; Mark M Yun; Yi-Zhong Wang; Rui-Ming Zhang; Xing-Kai Meng; Xiao-Hui Ou-Yang; Sheng Yun
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

3.  Cytotoxic dendritic cells generated from cancer patients.

Authors:  Daniela Lakomy; Nona Janikashvili; Jennifer Fraszczak; Malika Trad; Sylvain Audia; Maxime Samson; Marion Ciudad; Julien Vinit; Catherine Vergely; Denis Caillot; Pascal Foucher; Laurent Lagrost; Salem Chouaib; Emmanuel Katsanis; Nicolas Larmonier; Bernard Bonnotte
Journal:  J Immunol       Date:  2011-07-29       Impact factor: 5.422

4.  Subversion of pulmonary dendritic cell function by paramyxovirus infections.

Authors:  Antonieta Guerrero-Plata; Deepthi Kolli; Chao Hong; Antonella Casola; Roberto P Garofalo
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

5.  PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Authors:  Neale T Hanke; Collin J LaCasse; Claire B Larmonier; Darya Alizadeh; Malika Trad; Nona Janikashvili; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Eur J Immunol       Date:  2014-05-23       Impact factor: 5.532

6.  Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study.

Authors:  Ying Qiu; Mark M Yun; Ming Bao Xu; Yi Zhong Wang; Sheng Yun
Journal:  Int J Clin Oncol       Date:  2012-07-31       Impact factor: 3.402

Review 7.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

8.  Cytotoxic activity of dendritic cells as a possible mechanism of negative regulation of T lymphocytes in pulmonary tuberculosis.

Authors:  Ludmila V Sakhno; Marina A Tikhonova; Tamara V Tyrinova; Olga Yu Leplina; Ekaterina Ya Shevela; Sergey D Nikonov; Oleg A Zhdanov; Alexander A Ostanin; Elena R Chernykh
Journal:  Clin Dev Immunol       Date:  2012-09-29

9.  Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells.

Authors:  Tatjana Nikolic; Bart O Roep
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

10.  Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.

Authors:  Sébastien Anguille; Eva Lion; Jurjen Tel; I Jolanda M de Vries; Karen Couderé; Phillip D Fromm; Viggo F Van Tendeloo; Evelien L Smits; Zwi N Berneman
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.